106 related articles for article (PubMed ID: 26278141)
1. Salvage chemotherapy in metastatic colorectal cancer with the combination of capecitabine and mitomycin C.
Zygulska AL; Krzemieniecki K
Neoplasma; 2015; 62(5):793-7. PubMed ID: 26278141
[TBL] [Abstract][Full Text] [Related]
2. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
Lim DH; Park YS; Park BB; Ji SH; Lee J; Park KW; Kang JH; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Im YH; Kang WK; Park K
Cancer Chemother Pharmacol; 2005 Jul; 56(1):10-4. PubMed ID: 15782313
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine and mitomycin-C in the therapy of pretreated patients with metastatic colorectal cancer: single center retrospective study with 36 patients.
Vrdoljak E; Omrcen T; Boban M; Hrepic D
J BUON; 2008; 13(4):513-8. PubMed ID: 19145672
[TBL] [Abstract][Full Text] [Related]
4. Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G
Anticancer Res; 2013 Jun; 33(6):2743-6. PubMed ID: 23749935
[TBL] [Abstract][Full Text] [Related]
5. Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure.
Alkis N; Demirci U; Benekli M; Yilmaz U; Isikdogan A; Sevinc A; Ozdemir NY; Koca D; Yetisyigit T; Kaplan MA; Uncu D; Unek T; Gumus M
J BUON; 2011; 16(1):80-3. PubMed ID: 21674854
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
Comella P; Biglietto M; Casaretti R; De Lucia L; Avallone A; Maiorino L; Di Lullo L; De Cataldis G; Rivellini F; Comella G
Oncology; 2001; 60(2):127-33. PubMed ID: 11244327
[TBL] [Abstract][Full Text] [Related]
7. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
Shin SJ; Ahn JB; Choi HJ; Cho BC; Jeung HC; Rha SY; Chung HC; Roh JK
Cancer Chemother Pharmacol; 2008 Jan; 61(1):75-81. PubMed ID: 17375304
[TBL] [Abstract][Full Text] [Related]
8. Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study.
Rosati G; Rossi A; Germano D; Reggiardo G; Manzione L
Anticancer Res; 2003; 23(3C):2981-5. PubMed ID: 12926149
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin].
Zhou JF; Bai CM; Cheng YJ; Jia N; Shao YJ; Chen SC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Jun; 31(3):358-61. PubMed ID: 19621525
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
11. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.
Zhang P; Sun T; Zhang Q; Yuan Z; Jiang Z; Wang XJ; Cui S; Teng Y; Hu XC; Yang J; Pan H; Tong Z; Li H; Yao Q; Wang Y; Yin Y; Sun P; Zheng H; Cheng J; Lu J; Zhang B; Geng C; Liu J; Peng R; Yan M; Zhang S; Huang J; Tang L; Qiu R; Xu B;
Lancet Oncol; 2017 Mar; 18(3):371-383. PubMed ID: 28209298
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
Meyerhardt JA; Zhu AX; Enzinger PC; Ryan DP; Clark JW; Kulke MH; Earle CC; Vincitore M; Michelini A; Sheehan S; Fuchs CS
J Clin Oncol; 2006 Apr; 24(12):1892-7. PubMed ID: 16622264
[TBL] [Abstract][Full Text] [Related]
13. Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with metastatic colorectal cancer.
Mullin G; Sternschuss M; Landman Y; Sulkes A; Brenner B
World J Gastrointest Oncol; 2023 Nov; 15(11):1913-1924. PubMed ID: 38077638
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients.
Ozcelik M; Odabas H; Ercelep O; Yuksel S; Mert AG; Aydin D; Surmeli H; Isik D; Isik S; Oyman A; Oven Ustaalioglu BB; Aliustaoglu M; Gumus M
Clin Transl Oncol; 2016 Jun; 18(6):617-24. PubMed ID: 26459249
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer.
Choi DR; Yoon SN; Kim HS; Kim JH; Kim KY; Kim BC; Choi YK; Kim JB; Han B; Song HH; Zang DY
Cancer Chemother Pharmacol; 2015 Mar; 75(3):639-43. PubMed ID: 25630415
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
[TBL] [Abstract][Full Text] [Related]
17. 5-Fluorouracil, high-dose folinic acid and mitomycin C combination chemotherapy in previously treated patients with advanced colorectal carcinoma.
Seitz JF; Perrier H; Giovannini M; Capodano G; Bernardini D; Bardou VJ
J Chemother; 1998 Jun; 10(3):258-65. PubMed ID: 9669654
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis.
Brunner S; von Moos R; Mey U; Camenisch Gross U; Freyholdt T; Cathomas R
Oncol Res Treat; 2014; 37(11):646-52. PubMed ID: 25427581
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
